Activating mutations of KRAS are detected in over 95% of human pancreatic adenocarcinoma (PDA)1; and genetic mouse models have demonstrated that acquisition of oncogenic KRas is an initial event leading to pancreatic cancer2. Here, KRAS is linked to Patent ductus arteriosus.